



Five Prime Therapeutics, Inc.
Investor Relations Department
111 Oyster Point Blvd.
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: FPRX ¹

Last Trade:	23.61
Trade Time:	4:00 PM ET Monday, December 11, 2017
Change:	0.75 (3.281%)
Day Range	23.01 - 24.82
52-Week Range	21.41 - 53.90
Volume	812,404
Market Cap. (\$M)	683.037
Shares Out (M)	28.930

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immunoncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Monday, December 4, 2017*
[Five Prime Therapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference](#)
- Friday, November 10, 2017*
[Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting](#)
- Thursday, November 9, 2017*
[Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab \(anti-CSF-1 receptor antibody\) with Opdivo \(nivolumab\) in Patients with Advanced Solid Tumors](#)
- Tuesday, November 7, 2017*
[Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data](#)
- Tuesday, November 7, 2017*
[Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer \(SITC\) 32nd Annual Meeting](#)

Events [\[View all \]](#)

- Thursday, December 14, 2017 11:30 AM ET*
[BMO Capital Markets Prescriptions for Success Healthcare Conference](#)
- Friday, February 24, 2017*
[Annual Report \(10-K\)](#)
- Friday, March 31, 2017*
[Definitive Proxy Statement](#)
- Monday, November 6, 2017*
[Quarterly Report \(10-Q\)](#)
- Tuesday, August 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Friday, May 5, 2017*
[Quarterly Report \(10-Q\)](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

